Cerebrolysin vs Selank for focus
Short answer: For focus, more users report improvement with Cerebrolysin — 92% of 24 reports, versus 86% of 36 for Selank.
Cerebrolysin has 30 meta-analyses and 60 randomized trials on PubMed; Selank has 0 and 2.
Based on 228 reports about Cerebrolysin and 383 about Selank. Not medical advice.
| Cerebrolysin Peptide | Selank Peptide | |
|---|---|---|
| Users say it helped | 73%helped59 reports · medium confidence | 75%helped138 reports · high confidence |
| Verdict | Mostly positive | Mostly positive |
| Research | AResearch: Strong | CResearch: Limited |
| Meta-analyses / RCTs | 30 / 60 | 0 / 2 |
| Mainly used for | ||
| Anxiety % reporting improvement | 89% (9) | 97% (112) |
| Focus % reporting improvement | 92% (24) | 86% (36) |
| Mood % reporting improvement | 90% (20) | 90% (39) |
| Memory % reporting improvement | 97% (31) | 100% (9) |
| Sleep % reporting improvement | 100% (5) | 90% (10) |
| Common side effects | fatigue, headache, tingling, less sleep | headache, tolerance, injection site, tingling |
| Typical dose reported | Not listed | Not listed |
Ginkgo biloba extracts have shown the greatest cognitive and functional benefits, though their clinical significance remains uncertain, and certainty of evidence is overall low. Future trials should focus on a single VCI subtype, prioritize interventions with a strong mechanistic rationale, standardize diagnostic criteria, ensure adequate power for chosen outcomes, test against placebo, and implement FAIR data sharing to accelerate therapeutic discovery.
Alzheimers Dement, 2025 ↗“Cerebrolysin is by far the best nootropic I have ever used...my memory, recall ability, sensitivity to music, observance over my emotions, thinking faculties have all improved to a noticeable amount.”
“Selank has improved my anxiety immensely, and am able to focus on things clearly.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate